US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5190931A
(en)
|
1983-10-20 |
1993-03-02 |
The Research Foundation Of State University Of New York |
Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
|
US5175269A
(en)
|
1984-01-30 |
1992-12-29 |
Enzo Diagnostics, Inc. |
Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
IN165717B
(fr)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5082927A
(en)
|
1986-09-24 |
1992-01-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selectively cytotoxic IL-4-PE40 fusion protein
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
US5116742A
(en)
|
1986-12-03 |
1992-05-26 |
University Patents, Inc. |
RNA ribozyme restriction endoribonucleases and methods
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US4920143A
(en)
|
1987-04-23 |
1990-04-24 |
University Of British Columbia |
Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
|
US5171749A
(en)
|
1987-01-20 |
1992-12-15 |
University Of British Columbia |
Wavelength-specific cytotoxic agents
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5565566A
(en)
|
1987-04-24 |
1996-10-15 |
Discovery Therapeutics, Inc. |
N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
|
US5192788A
(en)
|
1988-05-23 |
1993-03-09 |
Georgia State University Foundation, Inc. |
Porphyrin antiviral compositions
|
US5109016A
(en)
|
1988-05-23 |
1992-04-28 |
Georgia State University Foundation, Inc. |
Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
US4968715A
(en)
|
1988-07-06 |
1990-11-06 |
Health Research, Inc. |
Use of purified hematoporphyrin trimers in photodynamic therapy
|
US5298508A
(en)
|
1988-07-19 |
1994-03-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Irreversible inhibitors of adenosine receptors
|
US5093349A
(en)
|
1988-07-20 |
1992-03-03 |
Health Research Inc. |
Photosensitizing agents
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
US5028594A
(en)
|
1988-12-27 |
1991-07-02 |
Naxcor |
Use of photodynamic compositions for cytotoxic effects
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
AU4746590A
(en)
|
1988-12-28 |
1990-08-01 |
Stefan Miltenyi |
Methods and materials for high gradient magnetic separation of biological materials
|
US5087617A
(en)
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
US5252720A
(en)
|
1989-03-06 |
1993-10-12 |
Board Of Regents, The University Of Texas System |
Metal complexes of water soluble texaphyrins
|
US5168053A
(en)
|
1989-03-24 |
1992-12-01 |
Yale University |
Cleavage of targeted RNA by RNAase P
|
US5149708A
(en)
|
1989-06-07 |
1992-09-22 |
University Of British Columbia |
Photosensitizing Diels-Alder porphyrin derivatives
|
US5144019A
(en)
|
1989-06-21 |
1992-09-01 |
City Of Hope |
Ribozyme cleavage of HIV-I RNA
|
US5272262A
(en)
|
1989-06-21 |
1993-12-21 |
City Of Hope |
Method for the production of catalytic RNA in bacteria
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5218088A
(en)
|
1989-11-02 |
1993-06-08 |
Purdue Research Foundation |
Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
US5087636A
(en)
|
1990-02-20 |
1992-02-11 |
University Of British Columbia |
Method to destroy malignant cells in mononuclear cell populations
|
US5180818A
(en)
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
US5053423A
(en)
|
1990-03-22 |
1991-10-01 |
Quadra Logic Technologies Inc. |
Compositions for photodynamic therapy
|
US5238940A
(en)
|
1990-03-22 |
1993-08-24 |
Quadra Logic Technologies Inc. |
Compositions for photodynamic therapy
|
US5135917A
(en)
|
1990-07-12 |
1992-08-04 |
Nova Pharmaceutical Corporation |
Interleukin receptor expression inhibiting antisense oligonucleotides
|
US5217966A
(en)
|
1990-09-13 |
1993-06-08 |
The Regents Of The University Of California |
Synthetic drug molecules that mimic metalloenzymes
|
US5202317A
(en)
|
1990-09-13 |
1993-04-13 |
The Regents Of The University Of California |
Synthetic drug molecules that mimic metalloenzymes
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
WO1993001286A2
(fr)
|
1991-06-28 |
1993-01-21 |
Massachusetts Institute Of Technology |
Therapie localisee utilisant des oligonucleotides
|
WO1993002192A1
(fr)
|
1991-07-15 |
1993-02-04 |
Repligen Corporation |
Compositions pf4 et procedes d'utilisation desdites compositions
|
US5257970A
(en)
|
1992-04-09 |
1993-11-02 |
Health Research, Inc. |
In situ photodynamic therapy
|
US5424297A
(en)
|
1992-04-27 |
1995-06-13 |
University Of Virginia Alumni Patents Foundation |
Adenosine dextran conjugates
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
WO1994025462A1
(fr)
|
1993-05-03 |
1994-11-10 |
The United States Of America, Represented By The |
Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5504090A
(en)
|
1994-03-30 |
1996-04-02 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
|
AU3374795A
(en)
|
1994-08-29 |
1996-03-22 |
Prizm Pharmaceuticals, Inc. |
Conjugates of vascular endothelial growth factor with targeted agents
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
US5670501A
(en)
|
1994-09-01 |
1997-09-23 |
Discovery Therapeutics, Inc. |
N-substituted 9-alkyladenines
|
US5622958A
(en)
|
1994-12-01 |
1997-04-22 |
Sloan-Kettering Institute For Cancer Research |
Enediyne quinone imines and methods of preparation and use thereof
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
WO1997027177A2
(fr)
|
1996-01-29 |
1997-07-31 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Derives de dihydropyridine-, pyridine-, benzopyrane- mono- et triazoloquinazoline, leur preparation, et utilsation comme antagonistes des recepteurs de l'adenosine
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
WO1997034634A1
(fr)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
|
SK9199A3
(en)
|
1996-07-24 |
1999-07-12 |
Celgene Corp |
2,6-dioxopiperidines, pharmaceutical composition them containing and their use
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
DK0920505T3
(da)
|
1996-08-16 |
2008-09-08 |
Schering Corp |
Pattedyrcelleoverfladeantigener og tilhörende reagenser
|
US5786360A
(en)
|
1996-11-19 |
1998-07-28 |
Link Technology Incorporated |
A1 adenosine receptor antagonists
|
PT994903E
(pt)
|
1997-06-24 |
2005-10-31 |
Genentech Inc |
Metodos e composicoes para glicoproteinas galactosiladas
|
EP1025228A4
(fr)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
|
WO1999022764A1
(fr)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
SK13642000A3
(sk)
|
1998-03-16 |
2001-04-09 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-yl)izoindolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
|
ES2246567T3
(es)
|
1998-04-15 |
2006-02-16 |
Brigham & Womens Hospital |
Composiciones para receptores inhibidores de celulas t y usos de las mismas.
|
WO1999054342A1
(fr)
|
1998-04-20 |
1999-10-28 |
Pablo Umana |
Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
|
US6326390B1
(en)
|
1998-08-25 |
2001-12-04 |
King Pharmaceuticals Reseach And Development, Inc. |
Use of adenosine A3 receptor antagonists to inhibit tumor growth
|
DE69930328T2
(de)
|
1998-08-27 |
2006-12-14 |
Spirogen Ltd., Ryde |
Dimere Pyrrolobenzodiazepine
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
GB9818732D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
US6313131B1
(en)
|
1999-02-16 |
2001-11-06 |
Upsher-Smith Laboratories, Inc. |
Method of kidney treatment
|
CN1342146A
(zh)
|
1999-03-18 |
2002-03-27 |
塞尔基因公司 |
取代的1-氧代-和1,3-二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
|
ES2568899T3
(es)
|
1999-04-09 |
2016-05-05 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
US6322771B1
(en)
|
1999-06-18 |
2001-11-27 |
University Of Virginia Patent Foundation |
Induction of pharmacological stress with adenosine receptor agonists
|
WO2001003720A2
(fr)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
CA2410510A1
(fr)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
ES2651952T3
(es)
|
2000-10-06 |
2018-01-30 |
Kyowa Hakko Kirin Co., Ltd. |
Células que producen unas composiciones de anticuerpo
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
GB0100624D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
CA2439410C
(fr)
|
2001-02-27 |
2011-09-06 |
William D. Figg |
Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
HUP0700103A3
(en)
|
2001-08-03 |
2012-09-28 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
WO2003026577A2
(fr)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-aminobenzyl ether dans des agents d'administration de medicaments
|
CN100423777C
(zh)
|
2001-10-25 |
2008-10-08 |
杰南技术公司 |
糖蛋白组合物
|
EP1482972A4
(fr)
|
2001-11-20 |
2005-11-23 |
Seattle Genetics Inc |
Traitement des troubles immunologiques au moyen des anticorps anti-cd30
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
AU2002356962C1
(en)
|
2001-12-12 |
2008-05-01 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
WO2003085118A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
CN1930288B
(zh)
|
2002-04-09 |
2012-08-08 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
EP1498491A4
(fr)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
EP1944320A1
(fr)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Variantes de l'immunoglobuline et leurs utilisations
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
EP2295976A1
(fr)
*
|
2003-03-08 |
2011-03-16 |
Auvation Ltd |
Marqueurs du cancer colorectal
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
AU2004244626A1
(en)
|
2003-05-23 |
2004-12-09 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
NZ547279A
(en)
|
2003-10-22 |
2008-04-30 |
Keck Graduate Inst |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
WO2005055808A2
(fr)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
|
WO2005053742A1
(fr)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition a base d'anticorps
|
CA2558195C
(fr)
|
2004-03-01 |
2012-11-06 |
Spirogen Limited |
Derives de 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepine-5-one en tant qu'intermediaires cles pour la preparation de pyrrolobenzodiazepines substituees c2
|
JP5166861B2
(ja)
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
ピロロベンゾジアゼピン
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
WO2006083289A2
(fr)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
EP2343320B1
(fr)
|
2005-03-25 |
2017-10-25 |
GITR, Inc. |
Anticorps contre gitr et leur utilisations
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
PL1899364T3
(pl)
|
2005-05-17 |
2020-08-24 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
JP5709356B2
(ja)
|
2006-01-13 |
2015-04-30 |
アメリカ合衆国 |
哺乳動物細胞における発現のためのコドン最適化IL−15およびIL−15R−α遺伝子
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
EP2111231A4
(fr)
|
2007-02-13 |
2010-12-15 |
Univ Northeastern |
Procedes et compositions pour ameliorer les reponses immunitaires
|
WO2008121420A1
(fr)
|
2007-03-30 |
2008-10-09 |
Memorial Sloan-Kettering Cancer Center |
Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive
|
US7615883B2
(en)
|
2007-06-06 |
2009-11-10 |
Meheen H Joe |
Wind driven venturi turbine
|
DK2170959T3
(da)
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
Antistoffer mod human programmeret dødsreceptor pd-1
|
NZ582330A
(en)
|
2007-06-27 |
2012-05-25 |
Marinepolymer Tech Inc |
COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
CA2703947C
(fr)
|
2007-10-26 |
2018-12-04 |
Governing Council Of The University Of Toronto |
Methodes therapeutiques et diagnostiques utilisant le tim-3
|
ES2640216T3
(es)
|
2007-12-07 |
2017-11-02 |
Miltenyi Biotec Gmbh |
Sistemas y métodos para procesamiento de células
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
US8609105B2
(en)
|
2008-03-18 |
2013-12-17 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
TGF−βアンタゴニスト多重標的結合性分子
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CA2734908A1
(fr)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
|
AU2009288289B2
(en)
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
JPWO2010030002A1
(ja)
|
2008-09-12 |
2012-02-02 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
WO2010065959A1
(fr)
|
2008-12-05 |
2010-06-10 |
Northeastern University |
Procédé de préparation de lymphocytes t antitumoraux résistants à l'adénosine pour immunothérapie adoptive
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
EP3192811A1
(fr)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Anticorps pd-1 et pd-l1 et leurs utilisations
|
RU2598710C2
(ru)
|
2009-04-30 |
2016-09-27 |
Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. |
Антитела к сеасам1 и способы их использования
|
AU2010282280B2
(en)
|
2009-08-14 |
2016-06-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of IL-15 to increase thymic output and to treat lymphopenia
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープCity of Hope |
形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
|
EP2504028A4
(fr)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
Inhibition simultanée de pd-l1/pd-l2
|
EP3112382A1
(fr)
|
2009-12-29 |
2017-01-04 |
Emergent Product Development Seattle, LLC |
Protéines à liaison hétérodimère et leurs utilisations
|
AU2011213609B2
(en)
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
KR101671360B1
(ko)
|
2010-04-15 |
2016-11-01 |
시애틀 지네틱스, 인크. |
표적화된 피롤로벤조디아제핀 접합체
|
WO2011159877A2
(fr)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
|
WO2012048340A2
(fr)
|
2010-10-08 |
2012-04-12 |
President And Fellows Of Harvard College |
Séquençage immunitaire à haut débit
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
ES2841983T3
(es)
|
2011-03-23 |
2021-07-12 |
Hutchinson Fred Cancer Res |
Método y composiciones para inmunoterapia celular
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(fr)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
|
BR112014011417B1
(pt)
|
2011-11-11 |
2021-10-13 |
Fred Hutchinson Cancer Research Center |
Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
|
CA2892371C
(fr)
|
2011-12-01 |
2021-01-19 |
The Brigham And Women's Hospital, Inc. |
Anticorps recombinants anti-ceacam1 pour la therapie de cancer
|
WO2013109759A1
(fr)
|
2012-01-17 |
2013-07-25 |
Northeastern University |
Méthodes et compositions de développement in vitro de lymphocytes t régulateurs immunosuppresseurs et utilisations de celles-ci
|
EP2814846B1
(fr)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
|
WO2013126726A1
(fr)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
|
KR20150009556A
(ko)
|
2012-05-03 |
2015-01-26 |
프레드 헛친슨 켄서 리서치 센터 |
증강된 친화성 t 세포 수용체 및 이의 제조 방법
|
EP3698809A1
(fr)
|
2012-07-31 |
2020-08-26 |
The Brigham & Women's Hospital, Inc. |
Modulation de la réponse immunitaire avec moyen se liant à tim-3 et ceacam-1
|
WO2014031687A1
(fr)
|
2012-08-20 |
2014-02-27 |
Jensen, Michael |
Procédé et compositions pour l'immunothérapie cellulaire
|
CN112430580A
(zh)
|
2012-10-02 |
2021-03-02 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
EP2906241B1
(fr)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Renforcement de la réponse immunitaire
|
CN104781789B
(zh)
|
2012-12-20 |
2018-06-05 |
三菱电机株式会社 |
车载装置
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
US10590483B2
(en)
|
2014-09-15 |
2020-03-17 |
Abvitro Llc |
High-throughput nucleotide library sequencing
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
CA2983937A1
(fr)
|
2015-04-27 |
2016-11-03 |
Abvitro Llc |
Procedes de sequencage, de determination, d'appariement, et de validation d'agents therapeutiques et d'antigenes specifiques de maladies
|